Long-term follow-up of enzyme therapy in people with Pompe disease
Follows children and adults with Pompe disease receiving enzyme replacement therapy over time.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Rotterdam, NetherlandsSee the site
- Registry title
- Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 156 people, planned
- Started
- 22 Jun 2007
- Planned end
- 22 Jun 2025
- Type of study
- Interventional
- Record updated
- 16 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults with confirmed Pompe disease who have symptoms and are approved to start enzyme therapy.
- Age
- No age limit. Children under 12 have a different blood-drawing plan.
- Sex
- All sexes can join.
- Disease stage
- Must have symptoms of Pompe disease: weak skeletal muscles, lower lung function (FVC below 80% sitting), or a thickened heart muscle.
- Earlier treatment
- Start of enzyme therapy must have been approved by the "indicatie commissie".
- Biomarker or test result
- Pompe disease confirmed by low α-glucosidase activity in white blood cells, skin cells or muscle, or by a known α-glucosidase gene mutation. A skin biopsy is needed to measure the remaining activity.
Main reasons for not taking part
- People who are not likely to benefit from treatment
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients should have a proven diagnosis of Pompe disease, which means that the diagnosis is confirmed by deficiency of α-glucosidase activity in leukocytes, fibroblasts or skeletal muscle, or by a documented mutation in the α-glucosidase gene. A skin biopsy is required to assess the level of residual α-glucosidase activity
- There is no age limit for participation in the study, but the protocol for children < 12 years of age differs in the amount of blood that will be drawn (appendix 1)
- Patients have had at least one evaluation through which the severity of the disease has been assessed and the urgency of enzyme therapy can be determined. During this evaluation at least pulmonary function and muscle strength and function will be assessed
- The order in which adult patients with Pompe disease will be enrolled is determined by the “indicatiecommissie” (appendix 2). For patients who show rapid progression of disease or for children the need for enzyme therapy will be discussed on a case by case basis
- The patient must have symptoms of Pompe disease being: Signs of skeletal muscle weakness, or Decreased pulmonary function (FVC < 80% in sitting position), or Cardiac hypertrophy
- Start of treatment has been approved by the “indicatie commissie”
- Written informed consent must be obtained from the patient and/or from the patient's parent/guardian if the patient is under 18 years of age (see section 6.1)
Who cannot take part
- Cases who are not likely to benefit from treatment
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
• Increase knowledge on the long term clinical effects of enzyme replacement therapy and to improve the level of care in children and adults with Pompe disease • Obtain data to support continuation of reimbursement by the Dutch health authorities after the initial 3 years • Assess the economic burden of Pompe disease (inventory of the costs of (medical) care, informal care and loss of productivity) and effects of enzyme therapy on these costs • Improve the efficacy (“doelmatigheid”) of enzyme therapy: • Development of guidelines when to start or stop enzyme therapy; • Should dosing be advised per kg body weight or per kg lean body mass • Safely install enzyme therapy at home • Learn more about atrophy and regeneration capacity of skeletal muscle in children and adults
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease; Long-term follow-up of patients receiving commercially available Myozyme
- Plain-language title
- Long-term follow-up of enzyme therapy in people with Pompe diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 December 2024